Introduction {#S0001}
============

Metformin is still considered as the first-line pharmacological treatment for the management of type 2 diabetes (T2DM) combined with life-style measures (diet and exercise).[@CIT0001] In T2DM patients with atherosclerotic cardiovascular (CV) disease, heart failure and/or renal disease, sodium-glucose cotransporter type 2 inhibitors (SGLT2is) should be added to metformin whatever the level of glycated hemoglobin (HbA1c), as they have demonstrated both a CV and renal protection in high-risk patients, independently of glucose control.[@CIT0001] In patients with T2DM but without such comorbidities, the objective is to reach individualized HbA1c target if not attained with metformin monotherapy. SGLT2is may be added to metformin,[@CIT0002],[@CIT0003] but are in competition with other glucose-lowering agents, especially dipeptidyl peptidase-4 inhibitors (DPP-4is).[@CIT0004],[@CIT0005] When compared to DPP-4is, SGLT2is have the advantage to promote weight loss and reduce arterial blood pressure, two effects that may contribute to the CV protection.[@CIT0006]

Most studies have been performed in non-Asian (mainly Caucasian) patients. However, some SGLT2is are commercialized in Asia (Japan, Korea, China, India), but not in North America or in Europe. Furthermore, Asian patients have a different phenotype of T2DM with a lower prevalence of obesity (yet an increased propensity for visceral adiposity) and a more marked defect in insulin secretion.[@CIT0007] These differences may impact the treatment response to glucose-lowering agents.[@CIT0008],[@CIT0009] For instance, glucagon-like peptide-1 receptor agonists (GLP-1 RAs)[@CIT0010],[@CIT0011] and DPP-4is[@CIT0012],[@CIT0013] exert a greater reduction in HbA1c in Asian than in non-Asian patients with T2DM. A recent meta-regression of randomized controlled trials (RCTs) indicated the hypoglycemic efficacy of SGLT2is/DPP-4is combination is higher in Asians than in other ethnic populations, and the differences in body mass index across ethnic groups may mediate this effect.[@CIT0014]

The primary renal mechanism of action of SGLT2is is an insulin-independent process.[@CIT0015],[@CIT0016] Nevertheless, both insulin secretion and insulin action could be indirectly improved when using an SGLT2i in patients with T2DM because of the reduction in glucose toxicity that is known to alter both beta-cell function and tissue insulin sensitivity.[@CIT0017],[@CIT0018] Thus, even if it is unknown whether there may exist inter-ethnic differences in the expression of sodium-glucose cotransporters in the renal tubules, different responses to SGLT2is might be observed between Asian and non-Asian patients with T2DM due to variable indirect effects on either insulin secretion or insulin action. A meta-analysis that compared the efficacy of SGLT2is showed no significant difference in HbA1c, body weight and systolic blood pressure (SBP) reductions between Asian and non-Asian patients with T2DM.[@CIT0019] However, this meta-analysis combined different types of background therapies, from diet and exercise alone to insulin therapy. Background therapy of patients with T2DM may influence the amplitude of the reduction in HbA1c when another glucose-lowering medication, including an SGLT2i, is added.[@CIT0003],[@CIT0020] The present work will restrict the analysis to a more homogeneous population, ie patients treated with metformin as monotherapy. This population is of special interest as the choice of the best glucose-lowering medication to be added to the first-line drug metformin[@CIT0001] remains a challenge for most clinicians, especially in primary care.[@CIT0021]--[@CIT0023]

The aim of this systematic review of RCTs is to compare the efficacy of SGLT2is versus placebo on glucose control, as assessed by changes in HbA1c and fasting plasma glucose (FPG), weight loss and arterial blood pressure in non-Asian versus Asian patients with T2DM treated with life-style and metformin. The effects of SGLTis on cardiovascular outcomes will not be considered in the present review.[@CIT0024] Of note, in EMPA-REG OUTCOME, reductions in the risk of CV outcomes and mortality with empagliflozin in Asian patients with T2DM and established CV disease were consistent with those observed in the overall trial population.[@CIT0025]

Materials and Methods {#S0002}
=====================

Data Sources and Search Strategy {#S0002-S2001}
--------------------------------

Electronic searches were performed in Pubmed, Embase and ClinicalTrials.gov site from January 1, 2010 to March 31, 2020 using the following search terms: "sodium-glucose cotransporter type 2 inhibitor" OR "SGLT2 inhibitor" OR "SGLT-2 inhibitor". A first filter was used to select RCTs. Each term corresponding to SGT2i was associated ("AND") with the term "metformin" OR with the term "placebo", separately and then in combination ([Figure 1](#F0001){ref-type="fig"}).Figure 1Flow chart of study selection process.**Abbreviations:** HbA1c, glycated hemoglobin; PD, pharmacodynamics; PK, pharmacokinetics; SGLT2i, sodium-glucose cotransporter 2 inhibitor.

In a complementary approach, the same search was performed for each SGLT2i commercialized worldwide (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin), in Japan (ipragliflozin, luseogliflozin, tofogliflozin), and in India (remoglifozin). The reference lists of several systematic reviews and meta-analyses dedicated to SGLT2is[@CIT0002],[@CIT0026],[@CIT0027] and of eligible related articles were manually examined to identify any additional publication relevant to the present study. Search for duplicates was done manually and using Endnote. Two independent researchers (A.S. and M.M., see acknowledgment) screened the literature, analyzed the selected studies and summarized the search results, using the same inclusion and exclusion criteria. Any resulting discrepancies were resolved by mutual discussion.

Inclusion and Exclusion Criteria {#S0002-S2002}
--------------------------------

Inclusion criteria were as follows: (a) RCTs with a duration of at least 12 weeks and a maximum of 52 weeks, which randomized at least 40 T2DM individuals in the arm of interest (SGLT2i) and used a placebo as comparator; (b) participants with T2DM and without renal insufficiency (estimated glomerular filtration rate \> 60 mL/min/1.73 m2), who were treated with lifestyle plus metformin monotherapy and had baseline HbA1c \> 7% (53 mmol/mol) at randomization; (c) detailed information available about the ethnic origin of the population; (d) in RCTs that tested different doses of SGLT2i (dose-finding studies), only the arms that evaluated commercialized doses of the SGLT2i were selected for the analyses; and (e) placebo-corrected reduction in HbA1c from baseline HbA1c (delta HbA1c) considered as the primary (or key-secondary) endpoint.

Exclusion criteria were as follows: (a) observational studies and non-randomized trials; (b) RCTs involving healthy subjects, non-diabetic patients with insulin resistance, patients with type 1 diabetes; (c) trials that randomized \< 40 patients with T2DM in the arm treated by an SGLT2i; (d) RCTs with a duration of less than 12 weeks or more than 52 weeks; (e) trials that evaluated initial combination of metformin plus an SGLT2i in drug-naïve T2DM patients; (f) trials that evaluated T2DM patients receiving other glucose-lowering agents than metformin monotherapy or that used an active glucose-lowering agent rather than a placebo as a comparator.

Data Extraction {#S0002-S2003}
---------------

The following data were extracted from all studies: (a) trial characteristics (RCT, first author, publication year, type and daily dose of SGLT2i added to metformin, duration of therapy, timing of primary evaluation); (b) participant characteristics (type of diabetes, antidiabetes treatment at randomization, sample size, baseline HbA1c; (c) ethnic groups separated as Asian versus non-Asian patients (RCTs that recruited ≥ 65% of non-Asian patients and \< 20% of Asian patients were classified in the category of non-Asian RCTs); d) primary endpoint (delta HbA1c: change in HbA1c from baseline to time of interest: for studies of 52-week duration, but in which the primary endpoint was considered at 24--28 weeks, the latter results were taken into account; for studies with extension beyond 52 weeks, primary results at 52 weeks were considered for the analysis); e) baseline levels and changes versus baseline of fasting plasma glucose (FPG), body weight (BW) and systolic blood pressure (SBP) considered as key-secondary endpoints.

Data Synthesis and Statistical Analysis {#S0002-S2004}
---------------------------------------

Mean (±SD) values were calculated from mean HbA1c levels at baseline and mean delta HbA1c (changes in HbA1c from baseline to time of primary endpoint) reported in the different RCTs. When SD was not available in the original publication, it was calculated using values of standard error of the mean (SE) or 95% confidence interval (95% CI). Placebo-corrected mean weighted difference (WMD), adjusted for the number of patients in each RCT, was compared in non-Asian and Asian patients with T2DM. Statistical differences versus baseline levels and between the two ethnic groups were calculated using paired and unpaired *t*-tests, respectively. Calculations and forest plots have been done using the review manager 5.3 program.

Results {#S0003}
=======

Study Characteristics {#S0003-S2001}
---------------------

The study selection process is depicted in [Figure 1](#F0001){ref-type="fig"}. A total of 3549 references were identified through the initial electronic search. When combined with the term "metformin", the number of references was reduced to 601. Subsequent combination with "placebo" allowed to reduce the number of references to 146. From this first set of references, we excluded citations based upon study characteristics after title/abstract evaluation (n=95) and subsequently other citations based upon inclusion/exclusion criteria after abstract/full-text evaluation (n=34). At the end of this search strategy, 17 RCTs that fulfilled all criteria were identified and were separated according to the ethnic group in two categories: RCTs that recruited Asian patients versus RCTs that recruited exclusively or mostly (\>65%) non-Asian patients. In the end, we identified 7 eligible RCTs (3 of them tested two doses, thus a total of 10 sets of data: n=1164) in Asian patients[@CIT0028]--[@CIT0034] and 10 eligible RCTs (6 of them tested two different doses, thus a total of 16 sets of data: n=2482) in non-Asian patients.[@CIT0035]--[@CIT0045] The results of one RCT were reported in two different complementary publications.[@CIT0038],[@CIT0039] In addition, two international studies recruited a mix population with both non-Asian and Asian patients with T2DM, one that tested ertugliflozin (respective proportions of ethnic groups not mentioned)[@CIT0046] and one that evaluated empagliflozin (53% non-Asian and 46% Asian patients).[@CIT0047] As no separate results were provided according to ethnicity, these two studies have not been included in the main analyses comparing Asian versus non-Asian patients and their results will be shown separately.

HbA1c Reduction in Non-Asian vs Asian Patients {#S0003-S2002}
----------------------------------------------

The effects of SGLT2is versus placebo on HbA1c in people with T2DM treated with metformin monotherapy are shown in [Table 1](#T0001){ref-type="table"} for Asian patients and in [Table 2](#T0002){ref-type="table"} for non-Asian patients. SGLT2i treatment was associated with a significant HbA1c reduction in both ethnic groups. No significant differences were observed neither in baseline HbA1c levels (7.98 ± 0.19 versus 7.89 ± 0.27, p=0.190) nor in the HbA1c reduction from baseline between Asian and non-Asian patients: WMD −0.60 (−0.68, −0.53) % versus −0.54 (−0.59, −0.49) %, respectively, p=0.568. As empagliflozin was not evaluated as add-on to metformin in Asian patients whereas tofogliflozin was not evaluated in non-Asian patients, we excluded these two studies and restricted the analysis to SGLT2is that were investigated in both ethnic populations (canagliflozin, dapagliflozin, ertugliflozin and ipragliflozin) and the overall results were not different (data not shown). Finally, no differences in the reduction in HbA1c were observed between Asian and non-Asian patients when studies were divided according to baseline HbA1c \< 8% (−0.54 ± 0.07 versus −0.53 ± 0.16, respectively, p=0.858) versus ≥ 8% (−0.76 ± 0.28 versus −0.59 ± 0.26, respectively, p=0.345). These data are summarized in a forest plot meta-analysis, which showed some heterogeneity between studies in both ethnic groups, Asian ([Figure 2](#F0002){ref-type="fig"}) and non-Asian ([Figure 3](#F0003){ref-type="fig"}). These results are in agreement with the reductions in HbA1c reported in the two studies that recruited a mix of Asian and non-Asian patients with T2DM treated with metformin alone: placebo-corrected least square mean −0.69% and −0.72% with the add-on of ertugliflozin 5 mg and 25 mg, respectively;[@CIT0046] −0.57% and −0.64% with the add-on of empagliflozin 10 mg and 25 mg, respectively.[@CIT0047]Table 1Effects of SGLT2is on HbA1c in Placebo-Controlled Randomized Clinical Trials That Recruited Asian Patients with T2DM Insufficiently Controlled on Metformin MonotherapyCharacteristicsSGLT2 InhibitorPlaceboPlacebo-Corrected Delta HbA1c\
Mean (95% CI)ReferencesCountriesSGLT2i\
Daily Dose (mg)Duration (Weeks)NBaseline HbA1c\
(Mean ± SD)HbA1c Delta vs Baseline\
(Mean ± SD)NBaseline HbA1c\
(Mean ± SD)HbA1c Delta vs Baseline\
(Mean ± SD)Ji et al 2015[@CIT0028]ChinaCanagliflozin 100181088.0 ± 0.9−1.03 ± 1.761107.9 ±0.9−0.51 ± 1.68−0.52 (−0.72, −0.32) p\<0.001Canagliflozin 300181127.8 ± 0.8−1.12 ± 1.691107.9 ± 0.9−0.51 ± 1.68−0.60 (−0.80, −0.40) p\<0.001Yang et al 2016[@CIT0029]China, India, South KoreaDapagliflozin 5241478.09 ± 0.72−0.82 ± 0.741458.13 ± 0.85−0.59 ± 1.06−0.59 (−0.76, −0.42) p\<0.001Dapagliflozin 10241528.17 ± 0.84−0.85 ± 0.721458.13 ± 0.85−0.62 ± 1.04−0.62 (−0.79,-0.45) p\<0.001Ji et al 2019[@CIT0030]ChinaErtugliflozin 5261708.10 ± 0.90−1.00 ± 0.901678.10 ±1.00−0.20 ± 0.80−0.8 (−1.0, −0.6) p\<0.001Ertugliflozin 15261698.10 ± 0.90−0.90 ± 0.801678.10 ±1.00−0.20 ± 0.80−0.7 (−0.9, −0.5) p\<0.001Kashiwagi et al 2015[@CIT0031]JapanIpragliflozin 50241128.25 ±0.72−0.87 ± 0.65568.38 ± 0.74+0.38 ± 0.70−1.30 (−1.50, −1.09) p\<0.001Lu et al 2016[@CIT0032]South Korea, TaiwanIpragliflozin 5024877.74 ± 0.78−0.94 ± 0.75837.75 ±0.71−0.47 ± 0.81−0.46 (−0.66, - 0.27) p\<0.001Min et al 2017[@CIT0033]South KoreaIpragliflozin 5024437.67 ± 0.85−0.97 ± 0.81397.62 ±0.78−0.31 ± 0.79−0.60 (−0.87, −0.34) p\<0.001Ikeda et al 2015[@CIT0034] (\*)JapanTofogliflozin 2012647.92 ±0.79−0.768 ± 0.59667.88 ±0.69−0.269 ± 0.59−0.5 (NA) p\<0.001[^1][^2] Table 2Effects of SGLT2is on HbA1c in Placebo-Controlled Randomized Clinical Trials That Recruited Non-Asian (Caucasian) Patients with T2DM Insufficiently Controlled on Metformin MonotherapyCharacteristicsSGLT2 InhibitorPlaceboPlacebo-Corrected Delta HbA1c with SGLT2i\
Mean (95% CI)ReferencesCountriesSGLT2i\
Daily Dose (mg)Duration (Weeks)NBaseline HbA1c\
(Mean ± SD)HbA1c Delta vs Baseline\
(Mean ± SD)NBaseline HbA1c\
(Mean ± SD)HbA1c Delta vs Baseline\
(Mean ± SD)Rosenstock et al 2012[@CIT0035]12 countries\
North America, South America, East Europe, IndiaCanagliflozin 10012647.83 ± 0.96−0.76 ± 0.97657.75 ± 0.83−0.22 ± 0.72−0.54 (NA) p\<0.001Canagliflozin 30012647.69 ± 1.02−0.92 ± 0.73657.75 ± 0.83−0.22 ± 0.72−0.70 (NA) p\<0.001Lavalle-Gonzalez et al 2013[@CIT0036]22 countries 70% White, 16% AsianCanagliflozin 100263687.9 ± 0.9−0.79 ± 0.773548.00 ± 0.9−0.17 ± 1.13−0.62 (−0.76, −0.48) p\<0.001Canagliflozin 300263677.9 ± 0.9−0.94 ± 0.773548.00 ± 0.9−0.17 ± 1.13−0.77 (−0.91, −0.64) p\<0.001Bailey et al 2010[@CIT0037]United States, Canada, Argentina, Brazil, MexicoDapagliflozin 5241378.17 ± 0.96−0.7 ± 0.861378.12 ± 0.96−0.31 ± 0.85−0.4 (NA) p\<0.001Dapagliflozin 10241357.92 ± 0.82−0.84 ± 0.821378.12 ± 0.96−0.31 ± 0.86−0.53 (NA) P\<0.001Bolinder et al 2012[@CIT0038] and Ljunggren et al 2012[@CIT0039]Europe (Bulgaria, Czech Republik, Hungary, Poland, Sweden)Dapagliflozin 1050897.19 ± 0.44−0.38 ± 0.55917.16 ± 0.53+0.02 ± 0.55−0.40 (−0.56, −0.23) p\<0.001Schumm-Draeger et al 2015[@CIT0040]Europe, South AfricaDapagliflozin 1016997.71 ± 0.71−0.55 ± 0.551017.94 ± 0.85−0.35 ± 0.68−0.29 (−0.45, −0.12) p\<0.001Rosenstock et al 2013[@CIT0041]16 countries Europe, United States, ArgentinaEmpagliflozin 1012717.91 ± 0.70−0.56 ± 0.63718.0 ± 0.7+0.15 ± 0.63−0.71 (NA) p\<0.001Empagliflozin 2512708.06 ± 0.8−0.55 ± 0.63718.0 ± 0.7+0.15 ± 0.63−0.70 (NA) p\<0.001Ross et al 2015[@CIT0042]Europe, North America, South AmericaEmpagliflozin 10162147.83 ± 0.73−0.64 ± 0.731077.69 ± 0.72−0.22 ± 0.72−0.42 (−0.60, −0.25) p\<0.001Empagliflozin 25162147.73 ± 0.73−0.72 ± 0.731077.69 ± 0.72−0.22 ± 0.72−0.50 (−0.68, −0.32) p\<0.001Rosenstock et al 2018[@CIT0043]65% White, 16% AsianErtugliflozin 5262078.1 ± 0.9−0.7 ± 0.92098.2 ±0.9−0.2 ± 0.9−0.7 (−0.9, −0.5) p\<0.001Ertugliflozin 15262058.1 ± 0.9−1.0 ± 0.92098.2 ± 0.9−0.2 ± 0.9−0.9 (−1.0, −0.7) p\<0.001Wilding et al 2013[@CIT0044]Europe and United StatesIpragliflozin 5012687.76 ± 0.66−0.65 ± 0.74667.68 ± 0.60−0.31 ± 0.753−0.34 (NA) p\<0.05Shestakova et al 2018[@CIT0045]RussiaIpragliflozin 50121108.39 ± 0.93−1.01 ± 0.85558.46 ± 0.96−0.77 ± 1.10−0.26 (−0.53, 0) p=0.048[^3] Figure 2Meta-analysis of placebo-controlled randomized clinical trials that investigated the effects of SGLT2is on HbA1c in Asian patients with T2DM insufficiently controlled on metformin monotherapy.**Abbreviations:** CI, confidence interval; HbA1c, glycated hemoglobin (mmol/mol); IV, inverse variance; SD, standard deviation; SGLT2i, sodium-glucose cotransporter type 2 inhibitor.Figure 3Meta-analysis of placebo-controlled randomized clinical trials that investigated the effects of SGLT2is on HbA1c in non-Asian (Caucasian) patients with T2DM insufficiently controlled on metformin monotherapy.**Abbreviations:** CI, confidence interval; HbA1c, glycated hemoglobin; IV, inverse variance; SD, standard deviation; SGLT2i, sodium-glucose cotransporter type 2 inhibitor.

Other Efficacy Parameters {#S0003-S2003}
-------------------------

The effects of SGLT2is versus placebo on FPG, BW and SBP, expressed as placebo-adjusted WMD, in Asian and non-Asian patients are shown in [Tables 3](#T0003){ref-type="table"} and [4](#T0004){ref-type="table"}, respectively. SGLT2i treatment was associated with a consistent and significant reduction in all three parameters in both ethnic groups. Reductions in diastolic blood pressure were generally about half of those noticed for SBP (data not shown). No significant differences were observed neither in baseline levels nor in SGLT2i-associated reductions (WMD) regarding FPG (−1.37 (−1.53, −1.22) mmol/l versus −1.37 (−1.47, −1.27) mmol/l, p=0.627) ([Table 5](#T0005){ref-type="table"}) and SBP (−4.53 (−5.53, −3.53) mmHg versus −4.06 (−4.83, −3.29) mmHg, p=0.223) ([Table 6](#T0006){ref-type="table"}) between Asian and non-Asian patients, respectively. Baseline BW was significantly lower in Asian compared to non-Asian patients (71.5 versus 88.0, p\<0.001). The BW reduction observed with SGLT2i tended to be slightly lower in Asian than in non-Asian patients when expressed in kg (−1.60 (−1.84, −1.37) kg versus −1.91 (−2.09, −1.73) kg, p=0.090), but this trend disappeared when changes were expressed in percentage of initial BW: −2.23 (−2.55, −1.90) % versus −2.16 (−2.37, −1.96) %, p=0.324) ([Table 6](#T0006){ref-type="table"}). These effects of SGLT2is on FPG, BW and SBP are illustrated in three forest plot meta-analyses (see [[Figures S1--S3](http://www.dovepress.com/get_supplementary_file.php?f=193528.pdf)]{.ul} in supplementary materials). Of note, no heterogeneity was detected between studies for BW and SBP, in contrast to results evaluating glucose control (HbA1c in [Figures 2](#F0002){ref-type="fig"} and [3](#F0003){ref-type="fig"} and FPG in [[Figure S1](http://www.dovepress.com/get_supplementary_file.php?f=193528.pdf)]{.ul}).Table 3Effects of SGLT2is on Fasting Plasma Glucose, Body Weight and Systolic Blood Pressure in Placebo-Controlled Randomized Clinical Trials That Recruited Asian Patients with T2DM Insufficiently Controlled on Metformin MonotherapyReferenceSGLT2i\
Daily Dose\
mgN\
SGLT2i/\
PlaceboBaseline FPG\
mmol/l\
Mean ± SD\
SGLT2i/\
PlaceboPlacebo-Adjusted Difference versus Baseline mmol/l\
Mean (95% CI)Baseline Body Weight Kg\
Mean ± SD\
SGLT2i/\
PlaceboPlacebo-Adjusted Difference versus Baseline kg\
Mean (95% CI)Baseline SBP mmHg\
Mean ± SD\
SGLT2i/\
PlaceboPlacebo-Adjusted Difference versus Baseline mmHg\
Mean (95% CI)Ji et al 2015[@CIT0028]Canagliflozin 100108/1108.7±1.9\
8.9±1.9− 1.4 (−1.9, −0.9)\
p\<0.00170.3±11.5\
69.9±12.5−2.2 (−3.1, −1.4)\
p\<0.001129.7±13.3\
129.8±14.3−2.6 (−5.6, 0.4)\
p=NACanagliflozin 300112/1108.7±1.9\
8.9±1.9−1.6 (−2.1, −1.1)\
p\<0.00171.1±11.8\
69.9±12.5−2.3 (−3.2, −1.5)\
p\<0.001129.9±14.3\
129.8±14.3−3.6 (−6.6, −0.6)\
p=NAYang et al 2016[@CIT0029]Dapagliflozin 5147/1459.0±2.2\
9.2±2.5−1.2 (−1.6, −0.9)\
p\<0.00170.8±12.2\
70.9±11.4−1.1 (−1.7, −0.6)\
p\<0.001129.1±14.4\
126.3±13.6−5.9 (NA)\
p=NADapagliflozin 10152/1459.0±2.2\
9.2±2.5−1.5 (−1.9, −1.1)\
p\<0.00171.4±12.0\
70.9±11.4−1.8 (−2.4, −1.3)\
p\<0.001127.0±13.7\
126.3±13.6−4.3 (NA)\
p=NAJi et al 2019[@CIT0030]Ertugliflozin 5170/1679.45±2.00\
9.21±2.09−1.69 (−2.03, −1.36)\
p\<0.00171.4±11.1\
70.1±12.4−1.8 (−2.3, −1.3)\
p\<0.001NA−5.3 (−7.7, −2.9)\
p=NAErtugliflozin 15169/1679.29±2.28\
9.21±2.09−1.54 (−1.88, −1.21)\
p\<0.00169.5±10.9\
70.1±12.4−2.0 (−2.5, −1.5)\
p\<0.001NA−4.1 (−6.5, −1.7)\
p=NAKashiwagi et al 2015[@CIT0031]Ipragliflozin 50112/568.98±1.66\
9.70±1.38−2.19 (−2.61, −1.77)\
p\<0.00168.5±13.9\
67.5±11.4−1.69 (−2.25, −1.12)\
p\<0.001126.3±13.6\
125.8±16.1−3.6 (NA)\
p=NALu et al 2016[@CIT0032]Ipragliflozin 5087/838.00±2.00\
7.67±1.52−0.78 (−1.17, −0.40)\
p\<0.00170.36±14.75\
70.45±12.44−1.24 (−1.92, −0.56)\
p\<0.001NA−5.5 (NA)\
p=NAMin et al 2017[@CIT0033]Ipragliflozin 5043/398.12±2.38\
7.68±1.78−1.19 (−1.78, −0.60)\
p\<0.00168.1±13.8\
69.0±12.2−1.53 (−2.44, −0.61)\
p=0.001NA−12.1 (NA)\
p=NAIkeda et al 2015[@CIT0034] (\*)Tofogliflozin 2064/668.74±1.88\
8.76±1.88−0.433 (NA)\
p\<0.0584.9±17.3\
83.73±19.2−1.81 (NA)\
p\<0.0001NA−2.6 (NA)\
p=NA[^4][^5] Table 4Effects of SGLT2is on Fasting Plasma Glucose, Body Weight and Systolic Blood Pressure in Placebo-Controlled Randomized Clinical Trials That Recruited Non-Asian (Caucasian) Patients with T2DM Insufficiently Controlled on Metformin MonotherapyReferenceSGLT2i\
Daily Dose\
mgN SGLT2i/\
PlaceboBaseline FPG\
mmol/l\
Mean ± SD\
SGLT2i/\
PlaceboPlacebo-Adjusted Difference vs Baseline mmol/l\
Mean (95% CI)Baseline Body Weight\
Kg\
Mean ± SD\
SGLT2i/\
PlaceboPlacebo-Adjusted Difference vs Baseline kg\
Mean (95% CI)Baseline SBP mmHg\
Mean ± SD\
SGLT2i/\
PlaceboPlacebo-Adjusted Difference vs Baseline mmHg\
Mean (95% CI)Rosenstock et al 2012[@CIT0035]Canagliflozin 10064/659.33±2.33\
9.11±2.11−1.60 (NA)\
p\<0.00187.7±15.5\
85.9±19.5−1.5 (NA)\
p\<0.001126.5±13.3\
125.2±9.8+ 2.3 (NA)Canagliflozin 30064/658.83±2.44\
9.11±2.11−1.60 (NA)\
p\<0.00187.3±15.9\
85.9±19.5−2.3 (NA)\
p\<0.001126.1±11.6\
125.2±9.8−3.6 (NA)Lavalle-Gonzalez et al 2013[@CIT0036]Canagliflozin 100368/1839.3±2.3\
9.1±2.1−1.70 (−2.0, −1.3)\
p\<0.00188.7±22.3\
86.7±22.5−2.5 (−3.1, −1.9)\
p\<0.001128.0±12.7\
128.0±12.7−5.4 (−7.3, −3.4)Canagliflozin 300367/1839.6±2.5\
9.1±2.1−2.2 (−2.6, −1.9)\
p\<0.00185.4±20.7\
86.7±22.5−2.9 (−3.5, −2.3)\
p\<0.001128.7±13.0\
128.0±12.7−6.6 (−8.5, −4.7)Bailey et al 2010[@CIT0037]Dapagliflozin 5137/1379.39±2.72\
9.19±2.57−0.86 (NA)\
p\<0.00184.7±16.3\
87.7±19.2−2.1 (NA)\
p\<0.001126.9±14.3\
127.7±14.6−4.1 (NA)Dapagliflozin 10135/1378.66±2.15\
9.19±2.57−0.97 (NA)\
p\<0.00186.3±17.5\
87.7±19.2−2.0 (NA)\
p\<0.001126.0±15.9\
127.7±14.6−4.9 (NA)Bolinder et al 2012[@CIT0038] and\
Ljunggren et al 2012[@CIT0039]Dapagliflozin 1089/918.2±1.4\
8.3±1.4−0.95 (−1.33, −0.57)\
p\<0.00192.1±14.1\
90.9±13.7−2.37 (−3.41, −1.32)\
p\<0.001135.9±NA\
133.3±NA−2.8 (−5.9, + 0.2)Schumm-Draeger et al 2015[@CIT0040]Dapagliflozin 1099/1018.62±2.01\
8.76±1.99−0.56 (−0.90, −0.22)\
p=0.00190.6±15.9\
88.8±15.3−1.73 (−2.44, −1.01)\
p\<0.001132.2±12.0\
133.4±11.9−1.9 (NA)Rosenstock et al 2013[@CIT0041]Empagliflozin 1071/719.61±2.00\
9.67±2.22−1.50 (NA)\
p\<0.00187.9±14.4\
87.7±15.7−1.5 (NA)\
p\<0.001132.4±NA\
136±NA−2.15 (NA)Empagliflozin 2570/7110.00±2.67\
9.67±2.22−1.78 (NA)\
p\<0.00190.5±16.9\
87.7±15.7−1.4 (NA)\
p\<0.01135.3±NA\
136±NA−6.3 (NA)Ross et al 2015[@CIT0042]Empagliflozin 10214/1078.9±2.9\
8.90±2.0−1.0 (−1.3, −0.6)\
p\<0.00189.10±19.0\
90.1±18.4−1.74 (−2.35, −1.13) p\<0.001131.6±14.6\
131.5±14.5−2.5 (−6.7, −1.6)Empagliflozin 25214/1078.7±1.5\
8.90±2.0−1.3 (−1.6, −0.9)\
p\<0.00188.7±18.6\
90.1±18.4−1.92 (−2.53, −1.31) p\<0.001131.0±14.6\
131.5±14.5−5.5 (−8.0, −2.9)Rosenstock et al 2018[@CIT0043]Ertugliflozin 5207/2099.3±2.5\
9.4±2.3−1.4 (NA)\
P\<0.00184.8±17.2\
84.5±17.1−1.7 (NA)\
p\<0.001130.5±NA\
129.3±NA−3.7 (NA)Ertugliflozin 15205/2099.3±2.5\
9.4±2.3−2.1 (NA)\
p\<0.00185.3±16.5\
84.5±17.1−1.6 (NA)\
p\<0.001130.2±NA\
129.3±NA−4.5 (NA)Wilding et al 2013[@CIT0044]Ipragliflozin 5068/668.5±2.0\
8.6±1.5−0.73 (NA)\
p=0.00886.7±13.7\
89.0±14.5−1.62 (NA)\
p\<0.001NA\
NA−3.3 (NA)Shestakova et al 2018[@CIT0045]Ipragliflozin\
50110/559.49±2.25\
9.76±2.40−0.68 (−1.30, −0.06)\
p=0.03292.7±16.2\
89.5±15.6−1.34 (−2.06, −0.61)\
p\<0.001NA\
NA−4.6 (NA)[^6] Table 5Differences Between Asian versus Non-Asian Patients with Type 2 Diabetes Regarding the Effects of SGLT2i on Glucose ControlParametersAsian Patients\
SGLT2i versus Placebo\
(n=1164 versus n=1088)Non-Asian Patients\
SGLT2i versus Placebo\
(n=2482 versus n=1857)P values**Glycated hemoglobin (HbA1c, %)** Baseline values (SGLT2i/placebo)7.98±0.19/7.99± 0.227.89±0.27/7.92±0.300.189/0.540 Delta versus baseline (absolute %)−0.60 (−0.68,-0.53)−0.54 (−0.59,-0.49)0.586 Delta versus baseline (relative %)−5.74 (−6.62, −4.87)−6.90 (−7.52, −6.28)0.880**Fasting plasma glucose (mmol/l)** Baseline values (SGLT2i/placebo)8.80±0.46/8.84±0.679.11±0.49/9.14±0.400.118/0.229 Delta versus baseline (mmol/l)−1.37 (−1.53, −1.22)−1.37 (−1.47, −1.27)0.627 Delta versus baseline (%)−15.34 (−17.05, −13.63)−15.24 (−16.36, −14.13)0.433[^7][^8] Table 6Differences Between Asian versus Non-Asian Patients with Type 2 Diabetes Regarding the Effects of SGLT2is on Body Weight and Systolic Blood PressureParametersAsian Patients\
SGLT2i versus Placebo\
(n = 1164 versus n = 1088)Non-Asian Patients\
SGLT2i versus Placebo\
(n = 2482 versus n = 1857)P values**Body weight (kg)** Baseline values (SGLT2i/placebo)71.6±4.8/71.2±4.588 3±2.5/87.7±1.9\<0.001/0.001 Delta versus baseline (kg)−1.60 (−1.84, −1.37)−1.91 (−2.09, −1.73)0.0890 Delta versus baseline (%)−2.23 (−2.55, −1.90)−2.16 (−2.37, −1.96)0.324**Systolic blood pressure (mm Hg)** Baseline values (SGLT2i/placebo)128.4±1.6/127.6±2.0130.2±3.1/130.2±3.60.1574/0.0738 Delta versus baseline (mm Hg)−4.53 (−5.53, −3.53)−4.06 (−4.83, −3.29)0.22290 Delta versus baseline (%)−3.58 (−4.96, −2.20)−3.19 (−3.81, −2.28)0.75874[^9][^10]

Discussion {#S0004}
==========

Our results show that the glucose-lowering efficacy of SGLT2is, when added to metformin monotherapy, is similar in non-Asian and Asian patients with T2DM, considering the reductions in HbA1c and in FPG. These data confirm a previous meta-analysis of all RCTs that investigated SGLT2is added to any type of glucose-lowering therapies ranging from diet alone to insulin regimen.[@CIT0019] We also recently reported similar antihyperglycemic effects of SGLT2is in non-Asian and Asian patients with T2DM and chronic kidney disease.[@CIT0048]

These results contrast with those previously reported with incretin-based glucose-lowering therapies. Indeed, several meta-analyses showed a greater glucose-lowering effect of DPP-4is[@CIT0012],[@CIT0013] and of injectable GLP-1 RAs[@CIT0010] in Asian compared with non-Asian patients with T2DM, a finding recently confirmed with the combination of DPP-4i/SGLT2i[@CIT0014] and with oral semaglutide.[@CIT0011] The difference between these pharmacological classes may be explained by the fact that SGLT2is exert their glucose-lowering effect independently of insulin,[@CIT0003],[@CIT0015],[@CIT0016] in contrast with the mode of action of DPP-4is (acting as incretin potentiators) and GLP-1 RAs (acting as incretin mimetics), which both enhance endogenous insulin secretion.[@CIT0049] It is known that Asian patients with T2DM have a more profound deficit in insulin secretion than non-Asian patients.[@CIT0007] Asian patients with T2DM are also leaner than non-Asian (Caucasian) patients. As a clear correlation between body mass index and HbA1c-lowering effect of DPP-4is was shown in Asian-dominant studies, but not in non-Asian-dominant studies, it has been suggested that DPP-4is may have better glucose-lowering efficacy in Asian patients with T2DM because they have lower BW compared to Caucasian patients.[@CIT0007],[@CIT0012] Obviously, such an inter-ethnic difference in the glucose-lowering efficacy is not observed with SGLT2is.

Our results confirm that SGLT2is when added to metformin monotherapy are associated with a significant BW reduction. Because of significantly lower BW in Asian compared to non-Asian patients at baseline, a slight numerical difference in the placebo-adjusted BW reductions was noticed when expressed in kg. However, the difference completely disappeared when results were expressed in percentage of baseline BW. The amount of weight loss in our analysis are in agreement with that previously reported with different SGLT2is and different dosages,[@CIT0050] including in studies in East-Asian patients.[@CIT0051] Previous studies have shown that the overall weight reduction seen with SGLT2is is mostly due to a reduction in body fat mass rather than to fluid loss.[@CIT0038] Weight loss is also accompanied by a reduction in visceral adiposity and ectopic (liver) fat.[@CIT0052],[@CIT0053] A significant reduction in SBP was observed with SGLT2i therapy, again of similar amplitude in Asian as in non-Asian patients. The amplitude of the reduction in SBP was consistent with what has been previously reported with SGLT2is,[@CIT0054] including in East Asian patients with T2DM.[@CIT0051] Overall, these findings confirm previous results where comparisons of the BW and blood pressure placebo-corrected changes between Asian and non-Asian patients did not show a significant difference between groups.[@CIT0019]

Because the range of baseline HbA1c was rather narrow (between 7.67% and 8.39%, with only one study with baseline HbA1c of 7.19%) in the placebo-controlled RCTs included in this meta-analysis, it was not possible to properly investigate the relation between the reduction in HbA1c and the baseline HbA1c levels. However, no difference in the reduction in HbA1c could be detected between Asian and non-Asian patients when studies with baseline HbA1c \<8 % versus ≥ 8 % were analyzed separately. By using a much larger set of data, we previously reported a significant relationship between the amplitude of the reduction in HbA1c and the baseline HbA1c levels with SGLT2is, and the slope of the relationship tended to be steeper with SGLT2is than that observed with DPP-4is.[@CIT0005] These findings are in agreement with the results of a head-to-head RCT, which showed that incremental reductions in HbA1c with increasing baseline HbA1c are greater with the SGLT2i empagliflozin compared with the DPP-4i sitagliptin as monotherapy, a trial that mainly recruited non-Asian patients with T2DM.[@CIT0055] A stratified analysis of studies carried out in East Asian patients with T2DM also showed that patients with higher HbA1c levels at baseline achieve a greater improvement in HbA1c after taking SGLT2is.[@CIT0051]

Among SGLT2is only commercialized in Asia, ipragliflozin was the most widely tested agent as added to metformin. Our results confirm a previous meta-analysis of RCTs that evaluated the effect of ipragliflozin (50--300 mg/day) added to metformin (alone or in combination with another glucose-lowering agent) and reported placebo-subtracted reduction in HbA1c averaging −0.66% (95% CI −0.79, −0.53).[@CIT0056] Surprisingly, no study evaluated the addition of empagliflozin in Asian patients treated with metformin monotherapy (empagliflozin was only investigated as monotherapy in one RCT in Japanese patients with diet-treated T2DM).[@CIT0057] There are very few head-to-head trials that compared the efficacy of two SGLT2is. None of the RCTs considered in the two present meta-analyses in Asian and non-Asian patients included a direct comparison of two SGLT2is, in addition to metformin with placebo used as control. A recent study showed that remogliflozin etabonate, a new SGLT2i commercialized in India, was noninferior to dapagliflozin when added to metformin in Indian patients with T2DM.[@CIT0058]

Our results may be compared with findings of another meta-analysis of nine RCTs that studied the effects of an SGLT2i added to metformin. It also reported higher reductions in HbA1c (−0.50%, 95% CI −0.62, −0.38), FPG (−1.12 mmol/l, 95% CI −1.38, −0.87), BW (−1.72 kg, 95% CI −2.05, −1.39)\] and SBP (−4.44 mm Hg, 95% CI −5.45, −3.43), versus metformin monotherapy.[@CIT0002] These results are closed to those reported in our study. Compared with sulfonylureas as second-line therapy in patients with T2DM inadequately controlled on metformin, SGLT2is are more effective in reducing HbA1c in the longer term (despite similar glycemic efficacy in a relatively short term), produce less hypoglycemic events and lead to greater reductions in BW and blood pressure.[@CIT0059] In comparison with DPP-4is, SGLT2is added to metformin resulted in a slightly greater reduction in HbA1c (overall changes versus baseline: −0.80±0.20% versus −0.71±0.23%, p=0.0354),[@CIT0005] while offering the advantage of a greater weight loss and a significant blood pressure reduction.[@CIT0006],[@CIT0021]

Our analysis focused on efficacy rather than on safety. The safety profile of SGLT2is has been extensively investigated and subject to huge discussion in recent years.[@CIT0060] This safety profile appears to be very similar in Asian versus non-Asian patients,[@CIT0061] as shown in pooled analyses of trials performed with dapagliflozin,[@CIT0062] canagliflozin,[@CIT0063] and empagliflozin,[@CIT0064] including for empagliflozin in East Asian patients.[@CIT0065] The overall safety profile of SGLT2is in East Asian patients with T2DM was comparable to that classically reported in non-Asian (Caucasian) patients:[@CIT0002],[@CIT0060] SGLT2is did not increase the risk of hypoglycemia and urinary tract infections, but did increase the risk of mycotic genital tract infections.[@CIT0051]

The role of SGLT2is in the management of T2DM among East Asians is an interesting area of research, given that East Asians have been proven to be uniquely different from Caucasians.[@CIT0066] The efficacy and safety of SGLT2is in East Asians with T2DM were investigated in a meta-analysis of 33 RCTs that randomized 8496 patients treated with SGLT2is as either monotherapy or add-on therapy compared with placebo or other antihyperglycemic medications.[@CIT0051] Compared with the control group, the use of SGLT2is improved HbA1c (WMD −0.73%; 95% CI −0.84, −0.61), lowered FPG (WMD −1.58 mmol/l; 95% CI −1.83, −1.34) and reduced body weight (WMD −1.73 kg; 95% CI −2.28, −1.17). These results are closed to those of our study. Because SGLT2is are the only oral glucose-lowering agents that have been shown to reduce BW and visceral adiposity, they represent an evidence-based therapeutic option for the management of overweight/obese patients with T2DM.[@CIT0053]

The strength of this study is that it analyzed a large set of homogeneous RCTs, all comparing the effects of an SGLT2i when added to metformin monotherapy in Asian versus non-Asian patients with T2DM. It provides consistent positive results concerning four main surrogate metabolic and clinical endpoints, ie HbA1c, FPG, BW and SBP. A first limitation is that our analysis was based on indirect comparison in the absence of available direct comparison in the literature. One large RCT recruited about half of the patients as Asian and about half as non-Asian, but did not give separate results for the two ethnic groups.[@CIT0047] A second limitation was the rather low number of patients included in some RCTs, which attenuates the statistical power of these studies. In addition, there was a significant between-study heterogeneity regarding improvement in glucose control (HbA1c and FPG). A third limitation is that the non-Asian population may be heterogeneous as besides a majority of Caucasians, it may also comprise Hispanics or Afro-americans. However, as no separate results were reported in the different studies, it was not possible to perform a comparison strictly focusing on Caucasians. A final limitation is the rather narrow range of HbA1c investigated as a majority of RCTs included T2DM patients with mean baseline HbA1c levels comprised between 7.70% and 8.40%. Thus, our analysis concerns patients with moderately poor glycemic control and cannot be extrapolated to patients with more severely uncontrolled diabetes. Nevertheless, this HbA1c range corresponds to that commonly seen in a large proportion of T2DM patients whose therapy should be intensified after failure of metformin monotherapy in routine clinical practice.

Conclusion {#S0005}
==========

In patients with T2DM insufficiently controlled with metformin monotherapy, the addition of an SGLT2i versus placebo was associated with consistent reductions in HbA1c, FPG, BW and SBP. No significant differences could be detected between Asian and non-Asian patients. These results confirm that SGLT2is exert their positive effects on several surrogate metabolic and clinical endpoints, independently of ethnicity and the underlying phenotype and pathophysiology of T2DM.
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[^1]: **Notes:** (\*) 62% patients on metformin monotherapy, 38% on diet alone. Results correspond to the whole group in absence of separate analysis.

[^2]: **Abbreviations:** CI, confidence interval; HbA1c, glycated hemoglobin (mmol/mol); N, number of patients; NA, not available; SD, standard deviation; SGLT2i, sodium-glucose cotransporter type 2 inhibitor.

[^3]: **Abbreviations:** CI, confidence interval; HbA1c, glycated hemoglobin (mmol/mol); N, number of patients; NA, not available; SD, standard deviation; SGLT2i, sodium-glucose cotransporter type 2 inhibitor.

[^4]: **Notes:** (\*) 62% patients on metformin monotherapy, 38% on diet alone. Results correspond to the whole group in absence of separate analysis.

[^5]: **Abbreviations:** CI, confidence interval; FPG, fasting plasma glucose; N, number of patients; NA, not available; SBP, systolic blood pressure; SD, standard deviation; SGLT2i, sodium-glucose cotransporter type 2 inhibitor.

[^6]: **Abbreviations:** CI, confidence interval; FPG, fasting plasma glucose; N, number of patients; NA, not available; SBP, systolic blood pressure; SD, standard deviation; SGLT2i, sodium-glucose cotransporter type 2 inhibitor.

[^7]: **Note:** Results (mean and 95% confidence interval) are expressed as absolute changes and as percentage changes from baseline values.

[^8]: **Abbreviation:** SGLT2i, sodium-glucose cotransporter type 2 inhibitor.

[^9]: **Note:** Results (mean and 95% confidence interval) are expressed as absolute changes and as percentage changes from baseline values.

[^10]: **Abbreviation:** SGLT2i, sodium-glucose cotransporter type 2 inhibitor.
